<DOC>
	<DOC>NCT01636284</DOC>
	<brief_summary>This study is to determine how effectively JX-594 (Pexa-Vec) will prolong life in patients with advanced Hepatocellular Carcinoma (HCC) who have not been previously treated with sorafenib, and the safe administration of JX-594 in five weekly IV infusions.</brief_summary>
	<brief_title>A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer</brief_title>
	<detailed_description />
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>KEY Histologic or cytologic confirmation of advanced primary hepatocellular carcinoma (HCC) Measurable tumor (at least one tumor with ≥1 cm LD of contrastenhancement during the arterial phase on CT scanning) ECOG performance status 0, 1 or 2 ChildPugh Class A; or ChildPugh Class B7 without clinically significant ascites Platelet count ≥50,000 plts/mm3 WBC count ≥2,000 cells/mm3 and ≤50,000 cells/mm3 Hemoglobin ≥10 g/dL Adequate liver function KEY Received sorafenib as previous treatment for HCC for more than 14 days History of severe exfoliative skin condition (e.g., eczema or atopic dermatitis requiring systemic therapy for &gt; 4 weeks) Prior treatment with JX594 Known significant immunodeficiency due to underlying illness (e.g. HIV/AIDS) and/or medication Severe or unstable cardiac disease Viable CNS malignancy associated with clinical symptoms Pregnant or nursing an infant Significant bleeding event within the last 12 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Liver Cancer</keyword>
	<keyword>HCC</keyword>
	<keyword>first line HCC</keyword>
	<keyword>Pexa-Vec</keyword>
	<keyword>JX-594</keyword>
</DOC>